Bringing the fundamentals into focus…
Back to Vertex Pharmaceuticals Incorporated
How Vertex Pharmaceuticals Incorporated stacks up
VRTX · against 1,336 other Healthcare companies
Valuation
55/ 100
Above the middle of the pack.
Ranked #596 of 1,337 · scores higher than 55% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 50–59, including VRTX · Click a bar to see the companies
Why valuation scores 55?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- EBITDA yield is close to the peer norm. EBITDA yield: 4.0% vs peer median 4.0%
- higher earnings for the price paid: stronger than 64% of peers. Earnings yield: 3.3% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 66% of peers. Free cash flow yield: 2.8% vs peer median 0.0%
Metric by metric
Position: dot = VRTX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | VRTX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 3.2% | 1.5% | 64% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 4.0% | 4.2% | 49% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 2.8% | -1.0% | 66% | 20% | |
| Book yieldHigher is better · 1,306 reported | 15.1% | 37.9% | 21% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around VRTXScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score